India, July 3 -- image credit- shutterstock

Bengaluru-based Biocon Biologics Ltd (BBL),a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced that the European Commission (EC) has granted marketing authorisation in the European Union (EU) for the biosimilars Denosumab, Vevzuo(R) and Evfraxy(R).

Vevzuo(R) is approved for the prevention of bone complications in adults with advanced cancers with bone involvement, as well as for the treatment of adults and adolescents with mature bone structure with giant cell tumours (GCTs) of the bone.

Evfraxy(R) is approved for the treatment of osteoporosis in postmenopausal men and women, hormonal ablation in men with prostate cancer at increased risk of fractures, a...